Wire · operational-macro
Replimune Group (REPL) Wins FDA Approval, Is The Valuation Still Too Rich?
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
Replimune Group received FDA accelerated approval for its TUDRIQEV product despite ongoing legal risks from a securities class action related to its RP1 melanoma program. The stock has experienced strong recent gains but trades at a premium price-to-book ratio compared to biotech peers, reflecting investor expectations tempered by significant current losses.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a pricing gap between FDA approval-driven optimism and a costly legal challenge. Prepare for sharp valuation swings as the class action unfolds and market expectations adjust.
◆ Coverage
1 source · 9 Aug 2026
◆ Related on Wire
◆ Topics